

#### <sup>26</sup>**Abstract**

27 Background: Marfan syndrome (MFS) is a rare genetic disorder affecting the vascular and <sup>28</sup>musculoskeletal systems. Exercise is classically contraindicated and there are no data on the 29 limitations associated with the syndrome and the benefits of training in this population. This 30 study aimed to characterise the quality of life (OoL) and physical capacity of patients with <sup>31</sup>MFS and to evaluate the benefits of a 3-month online personal training program.

<sup>32</sup>Methods: MFS patients were compared with healthy subjects (H-S) at baseline. They were 33 then randomized 1:1 into a training group (MFS-T) and a control group (MFS-C). The 34 training consisted of 2 supervised online training sessions per week at home for 3 months, and 35 the session program was selected based on the initial assessment. The main outcome measure 36 was QoL as assessed by the MOS SF-36. The evolution of parameters during training was 37 compared between MFS-T and MFS-C.

38 Results: At baseline, QoL in all dimensions was lower in MFS. Peak oxygen uptake 39 ( $V\square$  O<sub>2</sub>peak) was also 25% lower, as was muscle elasticity. Training significantly improved 40 1) QoL (+20.2±14.3 MFS-T *vs.* 0.7±0.5 MFS-C), 2) V-O2peak (+34% MFS-T *vs.* 14% MFS-<sup>41</sup>C), 3) muscle elasticity index (11.5±8.2 MFS-T *vs.* +1.2±1. 7 MFS-C), reduced blood <sup>42</sup>pressures during isometric squat (systolic -19±30 MFS-T *vs.* 0±6 MFS-C; diastolic -27±39 43 MFS-T *vs.* +2±15 MFS-C), reduced pulse wave velocity (PWV) at rest (-1.20±1.89 MFS-T <sup>44</sup>*vs.* -0.40±1.61 MFS-C) and after peak exercise (-0.42±0.45 MFS-T *vs.* 0.08±0.48 MFS-C). 45 Aorta diameter remained stable in both groups (MFS-T -0.19 $\pm$ 1.1 *vs.* 0.11 $\pm$ 0.78 MFS-C). 46 After training, QoL remained lower in MFS-T than in H-S, but peak  $V\square O_2$ , PWV at rest and 47 after exercise were similar to those of H-S.

<sup>48</sup>Conclusions: A 3-month online training program had a beneficial effect on QoL, 49 cardiovascular and muscular parameters in MFS without affecting aortic root diameter.

50

<sup>51</sup>**Keywords:** Marfan Syndrome, personalized training, exercise, e-rehabilitation.

#### <sup>52</sup>*Non-standard abbreviations and acronyms*

- 53 1RM: One repetition maximum<br>54 MFS: Marfan syndrome
- 54 MFS: Marfan syndrome<br>55 FBN1: Fibrillin-1
- 55 FBN1: Fibrillin-1<br>56 MFS-C: Marfan s
- 56 MFS-C: Marfan syndrome control<br>57 MFS-T: Marfan syndrome training
- 57 MFS-T: Marfan syndrome training<br>58 H-S: Healthy subjects
- 58 H-S: Healthy subjects<br>59 FB: Fat body
- 59 FB: Fat body<br>60 MM: Mass m
- 60 MM: Mass muscular<br>61 BMI: Body mass inde
- 61 BMI: Body mass index<br>62 EF: Eiection fraction
- 62 EF: Ejection fraction<br>63 LV: Left ventricle
- 63 LV: Left ventricle<br>64 GLS: Global longi
- 64 GLS: Global longitudinal strain<br>65 RV: Right ventricle
- 65 RV: Right ventricle<br>66 PWV: Pulse wave v
- 66 PWV: Pulse wave velocity<br>67 OUES: Oxygen uptake effic
- 67 OUES: Oxygen uptake efficiency slope<br>68  $V\square$  O<sub>2</sub> peak: Peak oxygen uptake
- $V \Box O_2$  peak: Peak oxygen uptake
- 69 VT1: First ventilatory threshold<br>70 VF: Minute ventilation
- 70 VE: Minute ventilation<br>71 V□CO<sub>2</sub>: Volume of CO
- $V \Box CO_2$ : Volume of  $CO_2$  produced per minute
- $72$  VE/V $\Box$ CO<sub>2</sub>: Ventilation/carbon dioxide output ratio
- 73 FEV1: Forced expiratory volume in one second<br>74 mFT: Muscular exercise testing
- 74 mET: Muscular exercise testing<br>75 HR: Heart rate
- 75 HR: Heart rate<br>76 SBP: Systolic b
- 76 SBP: Systolic blood pressure<br>77 DBP: Diastolic blood pressure
- 77 DBP: Diastolic blood pressure<br>78 CPET: Cardiopulmonary exerc
- 78 CPET: Cardiopulmonary exercise testing<br>79 Aix: Augmentation index
- 79 Aix: Augmentation index<br>80 TGF-B: Transforming gro
- 80 TGF-B: Transforming growth factor beta<br>81 TIMP: Tissue inhibitors of metalloprotein
- 81 TIMP: Tissue inhibitors of metalloproteinases<br>82 MMPs: Matrix metalloproteinases
- 82 MMPs: Matrix metalloproteinases<br>83 OoL: Quality of life
- 83 QoL: Quality of life<br>84
- 
- 85 85

#### <sup>86</sup>**Introduction**

87 Marfan syndrome (MFS) is an autosomal dominant genetic disorder caused by a pathogenic 88 variant in the gene encoding fibrillin 1 (*FBN1*), with more than 1,300 unique pathogenic 89 variants reported. MFS affects multiple systems, including the cardiovascular and 90 musculoskeletal systems  $1-4$  and is associated with altered quality of life (QoL)  $5$ . The fatal 91 risk associated with MFS is related to aortic aneurysm expansion leading to aortic dissection 92 which can be prevented by prophylactic surgery. To date, the main medical therapy to reduce 93 the cardiovascular impact of MFS is the use of betablockers and regular medical follow-up  $\delta$ . 94 There is currently no specific exercise program available and validated, and recommendations 95 still limit physical activity to minimize the risk of aortic dilation, dissection, and possible 96 aortic rupture  $6$ .

97

<sup>98</sup>The benefits of cardiopulmonary exercise training are well documented in the general 99 population and its importance is increasingly being emphasised in patients with various 100 cardiovascular diseases, including chronic coronary heart disease<sup>7,8</sup> and heart failure<sup>9</sup>. 101 However, there is a lack of clear data in patients with MFS. In fact, patients with MFS may 102 differ from other populations because MFS has been associated with a specific myopathy<sup>10</sup> 103 and there is concern that increasing the blood pressure (BP) during exercise may increase 104 aortic root dilatation and the risk of aortic dissection. Indeed, aortic dissection has been 105 reported following isometric exercise. Deconditioning may result from this concern and may 106 also contribute to the alteration in exercise capacity and QoL in patients with MFS.

107 In addition, recent animal studies suggest that regular endurance exercise may be beneficial 108  $\frac{11,12}{2}$ . Therefore, a personalised online training program in combination with standard care may 109 be beneficial in patients with  $MFS<sup>13</sup>$ .

and the state of th



#### <sup>119</sup>*Study population*

<sup>120</sup>MFS patients: Inclusion criteria for MFS patients were: 1) adult patients (18 to 75 years of <sup>121</sup>age); 2) presence of an FBN1 pathogenic variant; 3) ability to exercise; and 4) having health 122 insurance. Exclusion criteria for MFS patients were: patients with cardiovascular disease 123 unrelated to MFS, pregnant patients, history of aortic dissection, aortic diameter > 45 mm, 124 significant aortic regurgitation, uncontrolled resting hypertension (diastolic blood pressure > <sup>125</sup>90 mmHg and systolic blood pressure > 140 mmHg), unavailability by telephone, 126 participation in an experiment in the 3 months prior to screening, unwillingness or inability to 127 sign the informed consent form.

- 128 Healthy subjects were matched for age and sex.
- 

#### <sup>130</sup>*Study Design*

<sup>131</sup>MFS patients were randomized 1/1 into 2 groups: 1) MFS-C who did not benefit from the 132 training program and were assessed at baseline and after 3 months; 2) MFS-T who followed 133 the personalised e-training program for 3 months and were assessed at baseline and after 3 134 months of training.

- <sup>135</sup>All participants gave written informed consent before enrolment. The study complied with the
- 136 Declaration of Helsinki, the institutional ethics committee approved the study protocol
- <sup>137</sup>(#2020-A01751-38) and the French Society of Cardiology promoted the study.
- 138 It has been approved by Protection of Persons Committee SOUTH MEDITERRANEAN
- 139 CHU CIMIEZ HOSPITAL CS 91179 06003 NICE CEDEX 1.
- 140 The trial was prospectively registered at Clinical Trial NCT04553094
- 141<br>142
- <sup>142</sup>**Evaluation of patients**
- 

<sup>144</sup>*Quality of life assessment* 

145 The Medical Outcome Study Short Form - 36 (MOS SF-36) was used to assess OoL.<sup>14</sup>.

#### <sup>147</sup>*Echocardiography*

148 Patients with MFS underwent standard echocardiography and tissue Doppler imaging (Vivid 149 9 Dimension® ultrasound device - GE Healthcare). This study included calculation of left 150 ventricular ejection fraction (LVEF), calculation of E/A ratio. Aortic diameters were <sup>151</sup>measured at different levels (*i.e.,* ring, root, tubular aorta, arch, descending thoracic aorta and 152 abdominal aorta). 2D strain echocardiography was also performed to assess global systolic 153 longitudinal strain (GLS) of the LV and right ventricle (RV).

154

#### <sup>155</sup>*Body composition*

<sup>156</sup>Body composition was measured using a bioimpedance scale (Tanita Body Composition 157 Analyzer BC-420MA). Body weight and percentage of fat mass (BF%), muscle mass (MM%) 158 and water were assessed. Body mass index (BMI) was calculated using the following formula 159 BMI = kg / m2, where kg is the body weight in kilograms and m2 is the height in metres 160 squared.

#### <sup>162</sup>*Cardiopulmonary exercise training (CPET) and spirometry*

163 At rest, before exercise, an electrocardiogram (ECG) was taken (200S-Cardioline), SBP and 164 DBP were measured with an automatic tensiometer (METRONIK BL-6 1000) and pulse wave 165 velocity (PWV) was measured with a Popmètre®.

166 The patients then performed an incremental exercise on the ergocycle to assess their 167 cardiorespiratory capacity. The intensity of the exercise gradually increased by 10 W/min 168 until the patients voluntarily stopped. During the exercise, the patients' expired gases were 169 continuously analysed. Peak oxygen uptake ( $V\square$ O2peak) was determined as the highest value 170 achieved during exercise. The ventilatory threshold 1 (VT1), the oxygen uptake efficiency 171 slope (OUES), the ratio of ventilation (VE) to carbon dioxide production (V $\Box$ CO<sub>2</sub>) (VE/ 172 V- $V \square CO_2$ ) were calculated. Pulse wave velocity (PWV) was measured after the first ventilator 173 threshold.Heart rate (HR) and SBP And DBP were measured every 3 minutes, during the <sup>174</sup>CPET. If the SBP > 160 mmHg during the exercise (*i.e.,* CPET), the patient with MFS was 175 excluded from the study  $15-18$ . 176 Pulse wave velocity (PWV) was measured again after exercise.

177 HR at the first ventilatory threshold (VT1) (HRVT1) and HR at  $V\square O_2$  peak (HRpeak  $V\square O_2$ )

178 were recorded to adapt and personalise the training loads for the 3-month e-training program.

179 Peak and training HR were determined during CPET.

180 Forced vital capacity (FVC), forced expiratory volume in one second (FEV1) and peak 181 expiratory flow 25-75% (PEF25-75) were measured and FEV1/FVC was calculated.

182

<sup>183</sup>*Muscular exercise testing (mET)* 

<sup>184</sup>Lower limb muscle strength and maximal force contraction were measured during a 185 countermovement jump (cm), a squat jump (cm) and a one repetition maximum (1RM) based 186 on 3 consecutive squats using a linear encoder (Bosco System Platform Chronojump). 187 They then performed an isometric bodyweight squat. During the squat, blood pressure and 188 PWV were measured (Detailed Appendix 1). 189 Two vertical jump tests were performed: the countermovement jump (CMJ) and the squat 190 jump (SJ) using the Chronojump platform. The recovery value is the difference measured 191 between the heights of the two jumps. 192 <sup>193</sup>*Pulse wave analysis*  194 Pulse wave analysis was performed at rest, during exercise (*i.e.*, isometric squat and CPET) 195 and after exercise. Complete pulse wave analysis included cardiac index, reflection 196 coefficient, PWV, AIx, SBP and DBP. 197 - At rest before the exercise test. A comprehensive analysis was first performed at rest in 198 the supine position. The average of the three consecutive results obtained was used for 199 analysis. <sup>200</sup>- During the squat. Pulse wave velocity (PWV), systolic blood pressure (SBP) and

- 201 diastolic blood pressure (DBP) were then measured during the 'isometric squat' while 202 the patients were squatting with their knees bent at  $90^{\circ}$ , positioned on a step with their 203 toes halfway over the edge of the step. One sensor was placed on the second toe and 204 the other on the middle finger of the hand, while the cuff was placed on the left arm. 205 Only one assessment of arterial pressure was performed and PWV was measured <sup>206</sup>(PWV was continuously monitored).
- 207 At rest after the CPET exercise test. Finally, the complete analysis was repeated at rest 208 in the supine position after the CPET (average of 3 measurements).

8

209

#### <sup>210</sup>*3-month personalized online training program for Marfan patients*

211 The MFS patients in the MFS-T group completed the personalised 3-month e-training 212 program at home. The program consisted of 2 training sessions per week for a total of 24 213 sessions. The initial exercise intensity during the training sessions was chosen based on 214 HRVT1 and the HR peak achieved during CPET. The patient had to remain within this 215 intensity range.

216 Details of the training method and evaluations are described in Appendices 1 and 2. HR, DBP 217 and SBP were telemonitored during each training session and followed live either by 218 videoconference and/or by connected devices. This made it possible to check that patients 219 were achieving the target HR and to verify that SBP did not exceed 160 mmHg. Training 220 loads were adjusted weekly to achieve the best training effect based on heart rate and the RPE 221 (rate of perceived exertion) scale  $19,20$ . Finally, patients were frequently reminded of the 222 training program, 3 to 4 training sessions in advance, in order to increase their adherence to 223 the program.

#### <sup>225</sup>*Statistical analyses*

226 The study used 1:1 randomisation to form treatment and control groups to minimise potential 227 selection bias and maximise statistical power. The sample size was determined based on the 228 study objectives using 80% power and a 5% significance level. A mean difference of 13 229 points in QoL (physical component) with a standard deviation of 20 was estimated between 230 the trained group and the control group. The minimum number of subjects required in each 231 group was 38, but to allow for a 20% drop-out rate, the number of patients in each group was 232 increased to 46.

233 Statistical analyses were performed using GraphPad Prism 9.4.1 software (San Diego, CA, 234 USA). One-way ANOVA was used to compare the different groups (H-S, MFS-C, MFS-T) in 235 the pre- and post-training sessions. Two-way repeated measures ANOVAs were used to 236 identify pre-post differences in the MFS-C and MFS-T groups. Different models (*i.e.*, time, 237 group and group x time interaction) were used. When significant interactions were found, 238 Tukey's post hoc test was used. To compare the effect of training on the MFS-C and MFS-T 239 groups, we analysed the difference after 3 months - baseline and used a Student's t-test. Data 240 were presented as percentages (%) or mean  $\pm$  standard deviation. Statistical significance was 241 considered when P values were  $\leq 0.05$ . <sup>243</sup>**Results**  <sup>244</sup>A total of 105 subjects were recruited for the study (Figure 1). There were 70 MFS patients 245 and 35 healthy subjects. The characteristics of the participants are shown in Table 1. The H-S 246 were sex and age matched to the MFS patients, all of whom were receiving beta-blockers. 247 The MFS patients were heavier and taller than the H-S. Almost half of the MFS patients had 248 scoliosis and 61% had ankle sprains. The MFS patients also had dilation of the aorta and 249 global joint hypermobility. 250<br>251 <sup>251</sup>*Baseline : Comparison of MFS patients with matched controls*  252 QoL (Table 2) was significantly different between MFS and H-S in all eight dimensions 253 assessed ( $P < 0.05$ ). Physical function, the criterion used to calculate the power of the study, 254 was 55% and 68.97% lower in MFS-C and MFS-T, respectively, compared to H-S.  $V\square$ O<sub>2</sub>peak was 25% lower in MFS (MFS-C and MFS-T) compared to H-S (Figure 2a). PWV

256 was significantly higher in MFS immediately after CPET (Figure 2b),  $(P< 0.001)$ . SBP and

257 DBP were significantly higher in MFS than in H-S during isometric squat  $(+13\%$  and  $+44\%$ 

258 respectively; Figure 2c).

10 million and the contract of the contract of

259 The 1RM values were significantly lower in MFS patients compared to H-S ( $p < 0.001$ )

<sup>260</sup>(Figure 3a).

261 The aortic root diameter was similar in the MFS-C and MFS-T groups  $(38.1 \pm 4.1 \text{ mm} \text{ vs.})$ 

 $262$  38.7 $\pm$ 4.6 mm, NS) and did not increase after training (Figure 2d).

- 
- <sup>264</sup>*Characteristics of training sessions*

265 The duration of the training session, peak and mean heart rate during the training session,

266 perceived exertion during the training session and blood pressure at the beginning, middle and

- 267 end of the training session were recorded and are shown in Table 3.
- 

```
269Main effects of a 3-month personalized online training program in MFS patients: Δ: post -
```
<sup>270</sup>*pre* 

<sup>271</sup>All dimensions of QOL improved significantly more in the MFS-T group than in the MFS-C

272 group after training (Table 2). The main criterion, physical function, increased by 33% in the

273 MFS-T group but remained significantly lower than in the H-S group ( $P < 0.0001$ ). In

274 addition, a significant 31% reduction in pain was observed in the MFS-T group ( $P < 0.0001$ ).

275  $O_{2\text{peak}}$  increased significantly more in the MFS-T group that in the MFS-C group (P<0.05)

276 (Figure 2a). Actually, after training,  $VO_{2peak}$  in MFS-T group was not significantly different

277 from  $\text{VO}_{2\text{peak}}$  in H-S (P=0.057). (26.5 $\pm$ 4.8 ml.min<sup>-1</sup>.kg<sup>-1</sup> vs. 29.4 $\pm$ 7.6 ml.min<sup>-1</sup>.kg<sup>-1</sup>, NS).

278 PWV immediately after CPET decreased significantly more in the MFS-T group than in the

279 MFS-C group (5.24±0.9 m/s-1 *vs.* 5.69±0.74 m/s-1, P<0.0001) (Figure 2b). In fact, the post-

280 training PWV in the MFS-T group was close to the PWV in the H-S group  $(5.24 \pm 0.74 \text{ m.s-1})$ 

<sup>281</sup>MFS-T *vs.* 4.65±0.73 m.s-1 H-S, NS).

282 1 RM increased significantly more in MFS-T than in MFS-C  $(+17 \text{ kg} \text{ vs.} + 9 \text{ kg}, \text{P}<0.001)$ 

283 (Figure 3a) although it remained significantly lower than in H-S  $(81.9\pm 21.9 \text{ kg})$  *vs.*  $133\pm 77 \text{ kg}$ ,

- <sup>284</sup>P<0.05). The Elasticity Index increased significantly more in the MFS-T than in the MFS-C
- <sup>285</sup>(+9.09±1.46 cm MFS-T *vs.* 0.03±1.45 cm MFS-C, P < 0.001) (Figure 3b).
- 

<sup>287</sup>Blood pressure decreased significantly more in the MFS-T than in the MFS-C during 288 isometric squat exercise (sBP -19 $\pm$ 30 MFS-T *vs.* 0 $\pm$ 6 MFS-C; dBP -27 $\pm$ 39 MFS-T *vs.* +2 $\pm$ 15 289 MFS-C;  $P < 0.02$ ). SBP and dBP were lower after training in the MFS-T group than in the <sup>290</sup>MFS-C group (sBP: 148±15 mmHg MFS-T *vs.* 162±18 mmHg MFS-C, P < 0.05; dBP: 94±8 291 mmHg $\pm$ 18 mmHg MFS-T *vs.* 113 $\pm$ 20 mmHg MFS-C, P < 0.001) (Figure 2c). In the MFS-T 292 group, sBP after training was similar to that in the H-S group  $(148\pm11 \text{ mmHg} \text{ vs. } 143\pm16 \text{ m})$ <sup>293</sup>mmHg, NS), but dBP tended to be higher (94±8 mmHg±7.37 mmHg *vs.* 78±14 mmHg, NS). <sup>294</sup>Aortic root diameters remained stable and were similar in MFS-T and MFS-C after training <sup>295</sup>(38.1±4.1 mm *vs.* 39.1±4.4 mm, NS; Figure 2d). In fact, during training, aortic diameter 296 tended to decrease in MFS-T and increase in MFS-C, but this difference was not statistically 297 significant (0.11±0.78 *vs.* -0.19±1.12 mm; p=0.74) (Figure 2d).

#### <sup>299</sup>*Cardiovascular and respiratory effects of a 3-month personalized e-training program in*

<sup>300</sup>*MFS patients* 

301 The e-training program reduced the Aix and the reflection coefficient and increased the 302 elasticity index in the MFS-T group compared to the MFS-C group (Table 4). It also reduced <sup>303</sup>PWV at rest, during a squat and after CPET in the MFS-T group compared to the MFS-C 304 group. The reduction in SBP with training was greater in the MFS-T group compared to the <sup>305</sup>MFS-C group at rest, during a squat and during the recovery period immediately after CPET, 306 but not during CPET. Finally, no significant differences in Tiffeneau index and PEF 25-75 307 were found between MFS-C and MFS-T after the exercise program.

#### <sup>309</sup>*Dropout rates*

310 The overall dropout rate was 25%. However, it was lower in the MFS-T group (17%) than in

311 the MFS-C group  $(42%)$  (Figure 1).

313

#### <sup>315</sup>**Discussion**

316 In this randomized and controlled study, we show that 3 months of personalised home-317 based training significantly restores the QoL of MFS patients, in particular the main criterion 318 "physical function", increases exercise capacity as measured by  $V\square O_2$  peak and muscle 319 strength as measured by 1RM, and improves arterial compliance as shown by a decrease in <sup>320</sup>PWV. These changes can be attributed to the training program we proposed to our patient, 321 thanks to the randomized control design of our study, which made it possible to compare the 322 evolution of each parameter after the 3-month period in the 2 groups (control group, without 323 training, called MFS-C, and training group, called MFS-T). The results indicate a beneficial 324 cardiopulmonary, muscular and vascular effect of training in this population. In addition, 325 training reduced resting and exercise sBP and dBP, which may also be beneficial in the long 326 term, and no detrimental effect on aortic root diameter was observed.

<sup>327</sup>In our program, each exercise session was individualised based on the CEPT at 328 baseline. The intensity of the exercise was chosen to keep the heart rate above the heart rate 329 observed at the first ventilator threshold during CPET and below the peak heart rate observed 330 during CPET. The first training session was conducted in the hospital under medical 331 supervision to monitor blood pressure and heart rate during the exercises proposed for the 332 training sessions. All subsequent sessions were carried out at home. During the course of the 333 program, the intensity of the home training sessions was adjusted on the basis of the perceived

334 exertion scale and the heart rate recorded by the patient during the previous training session.

335 This allowed for a personalised home-based program with maximum safety and efficiency.

 $336$  To our knowledge, there is only one study of exercise training in people with MFS  $^{15}$ . 337 In this observational study of a 3-week low-intensity exercise program in 18 MFS patients, 338 the authors reported positive effects on mental health, fatigue and exercise capacity. The 339 effect on aortic root diameter was not reported in this paper. However, a beneficial effect on 340 the aortic root has been suggested in MFS mice<sup>11,12</sup> : in this mouse model, moderate-intensity 341 exercise reduced the growth rate of aortic diameter and the risk of aortic rupture in exercised 342 mice compared with their sedentary counterparts. These protective effects were achieved with 343 exercise at intensities between 55 and 65% of  $V\square O_2$  peak.

344 Changes in QoL in patients with Marfan syndrome have been reported previously<sup>21,22</sup>. 345 However, no intervention has been shown to improve QoL in this population. The beneficial 346 effects of exercise training on QoL in patients with cardiovascular disease have been well  $347$  documented <sup>23,24</sup>, but data on the effects of training in patients with MFS are scarce. We show 348 that exercise improves all dimensions of QoL (Table 4). The dropout rate may also indirectly 349 reflect the perceived benefit of the training program by patients: in our study, the dropout rate <sup>350</sup>was much higher in the control group than in the training group (42% *vs.* 17%). Training may <sup>351</sup>become an important tool to limit the decline in QoL previously reported in the MFS 352 population<sup>22</sup>.

353 The functional limitation of MFS patients is evidenced by the  $25\%$  lower VO<sub>2peak.</sub>at 354 baseline when compared to healthy subjects. This result is in keeping with two previous small 355 studies  $25,26$ , and may partly explain the altered QoL in this population. Betablockade may 356 participate in this decreased peak  $V \Box O_2$ , as all MFS patients were receiving this therapy: in 357 normal suhjects<sup>27</sup>, betablockade has been associated with decreased peak  $V\square O_2$  by 5 to 15%, 358 and therefore it is unlikely that betablockade does account for the entire difference between

359 healthy subjects and MFS patients. Beyond  $V \Box O_2$ , a number of parameters are altered in this 360 population, such as maximal strength and elasticity index in the muscular component of the 361 lower limbs (already reported by 2 previous studies  $25,26$ ) which may also participate in the 362 altered QoL.

363 The training program may be beneficial beyond the increase in peak  $V \Box O_2$  and 364 improved QoL: the training program increased pulmonary parameters such as Tiffeneau index 365 and PEF25-75%, which increased to values similar to those of healthy subjects (Table 3). The 366 3 muscle components were also increased: 1/ increase in muscle mass, 2/ increase in muscle 367 strength, 3/ improvement in muscle elasticity. Finally, and perhaps more importantly, PWV <sup>368</sup>was increased at baseline, during CPET and during the recovery phase, as was the 369 augmentation index (Aix), all of which indicate more rigid arteries in the patients. Increased 370 stiffness may be responsible for greater recoil and therefore increased stress on the proximal 371 aorta, which has been associated with increased aortic root dilatation (ref) and may be related  $1372$  to the altered vasodilator mechanism in response to acute exercise in MFS patients  $6.28$ . 373 During the exercise program, PWV and Aix decreased. These effects may be beneficial in the <sup>374</sup>long term and are consistent with results from animal studies showing that exercise improves  $375$  aortic cellular structure and, in particular, arterial compliance  $11,12$ . This beneficial effect 376 should be additive to the expected benefit associated with lower blood pressure resulting from 377 the lowering effect of training on blood pressure rise during exercise. Because of all these 378 indirect haemodynamic effects, one would expect that exercise would actually reduce the rate 379 of aortic root dilatation in this population. We did not see a decrease in aortic root dilatation 380 in our study, as has been reported in the mouse, but neither did we see an increase in 381 diameter. Obviously, our statistical power is too low: it took more than 4 years and more than 382 1000 subjects to suggest that sartan might possibly lead to a reduction in the rate of aortic root 383 dilatation<sup>29</sup>.

384 This benefit can be expected with a minimum of risk: during the CPET and the 385 muscular exercise test (mET), the increase in blood pressure in MFS patients never exceeded 386 160 mmHg. It is important to note that, despite the limited increase in blood pressure, high 387 heart rates were achieved during the training session, as shown in Table 3 (e.g. an average of <sup>388</sup>85% of peak HR). This suggests that vigorous intensity exercise can be proposed without risk. 389 It is possible that the lower peak blood pressure observed during CPET at baseline  $(145±19.5$ 390 *vs.*  $188\pm46.8$ ;  $p<0.001$ ) was related to the use of beta-blocker therapy in all patients.

<sup>391</sup>In conclusion, MFS patients have altered QoL and exercise capacity, both of which 392 can be improved by supervised home exercise training. We also show that many <sup>393</sup>haemodynamic parameters are improved by training, which may translate into lower aortic 394 stress and therefore limit aortic root dilatation, although we were not able to show such an 395 effect in a short period of time in a limited population.

#### <sup>397</sup>**Study limitations**

<sup>398</sup>The program used during the training session was individualised and close monitoring of <sup>399</sup>heart rate and perceived exertion was carried out throughout the training period for all 400 patients. This takes time and may limit the reproducibility of the results obtained here. 401 However, a website is being set up to facilitate the adaptation of the sessions and to provide 402 all the necessary information to the patients. The size of the population is limited, but the 403 effect of training observed is impressive and unlikely to be the result of chance. Finally, the 404 population included was selected to be low-risk and the applicability of the results obtained in 405 higher-risk patients, who may benefit more from the training session, is unknown, particularly 406 because of the haemodynamic risk.

407

#### <sup>408</sup>**Acknowledgments**

It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.05.16.23289922;](https://doi.org/10.1101/2023.05.16.23289922) this version posted May 18, 2023. The copyright holder for this preprint

- <sup>409</sup>The authors dedicate this work to the patients who participated in the study and to all the
- 410 healthcare professionals in the Marfan Syndrome Reference Center in Hopital Bichat. This
- 411 study was presented at the European Days of the French Society of Cardiology in January
- 412 2022.
- 413
- <sup>414</sup>**Sources of Funding**
- <sup>415</sup>The study was sponsored by the Marfan Association, Multi-Fava, and Avenir Foundation.
- 
- <sup>417</sup>**Disclosures**
- 418 The authors have no conflict of interest to report
- <sup>419</sup>**References**
- 420 1. Rahman MAE, Haase D, Rentzsch A, Olchvary J, Schäfers H-J, Henn W, Wagenpfeil<br>421 S. Abdul-Khalia H. Left Ventricular Systolic Dysfunction in Asymptomatic Marfan 421 S, Abdul-Khaliq H. Left Ventricular Systolic Dysfunction in Asymptomatic Marfan<br>422 Syndrome Patients Is Related to the Severity of Gene Mutation: Insights from the 422 Syndrome Patients Is Related to the Severity of Gene Mutation: Insights from the 423 Novel Three Dimensional Speckle Tracking Echocardiography. PLOS ONE. 423 Novel Three Dimensional Speckle Tracking Echocardiography. *PLOS ONE*.<br>424 2015:10:e0124112.doi:10.1371/journal.pone.0124112
- 424 2015;10:e0124112. doi: 10.1371/journal.pone.0124112<br>425 2. Alpendurada F, Wong J, Kiotsekoglou A, Banya W, C 425 2. Alpendurada F, Wong J, Kiotsekoglou A, Banya W, Child A, Prasad SK, Pennell DJ, 426 Mohiaddin RH. Evidence for Marfan cardiomyopathy. *Eur J Heart Fail.* 426 Mohiaddin RH. Evidence for Marfan cardiomyopathy. *Eur J Heart Fail.*<br>427 2010;12:1085-1091. doi: 10.1093/eurjhf/hfq127 427 2010;12:1085-1091. doi: 10.1093/eurjhf/hfq127<br>428 3. Behan WMH, Longman C, Petty RKH, Comeg
- 428 3. Behan WMH, Longman C, Petty RKH, Comeglio P, Child AH, Boxer M, Foskett P, 429 Harriman DGF. Muscle fibrillin deficiency in Marfan's syndrome myopathy. *Journal* 429 **Harriman DGF. Muscle fibrillin deficiency in Marfan's syndrome myopathy.** *Journal* 430 of *Neurology, Neurosurgery & Psychiatry.* 2003;74:633-638. doi: <sup>430</sup>*of Neurology, Neurosurgery & Psychiatry*. 2003;74:633-638. doi: 431 10.1136/jnnp.74.5.633<br>432 4. Giske L. Stanghelle J
- 432 4. Giske L, Stanghelle JK, Rand-Hendrikssen S, Strom V, Wilhelmsen JE, Roe C.<br>433 Pulmonary function, working capacity and strength in young adults with Marfan 433 Pulmonary function, working capacity and strength in young adults with Marfan syndrome. *J Rehabil Med*. 2003;35:221-228. doi: 10.1080/16501970306095
- 434 syndrome. *J Rehabil Med.* 2003;35:221-228. doi: 10.1080/16501970306095<br>435 5. Peters KF, Kong F, Horne R, Francomano CA, Biesecker BB. Living wi 435 5. Peters KF, Kong F, Horne R, Francomano CA, Biesecker BB. Living with Marfan syndrome I. Perceptions of the condition. *Clinical Genetics*. 2001;60:273-282. doi: 436 syndrome I. Perceptions of the condition. *Clinical Genetics*. 2001;60:273-282. doi:<br>437 10.1034/i.1399-0004.2001.600405.x 437 10.1034/j.1399-0004.2001.600405.x<br>438 6. Milewicz DM, Braverman AC, De l
- 438 6. Milewicz DM, Braverman AC, De Backer J, Morris SA, Boileau C, Maumenee IH, Jondeau G, Evangelista A, Pyeritz RE. Marfan syndrome. Nat Rev Dis Primers. 439 Jondeau G, Evangelista A, Pyeritz RE. Marfan syndrome. *Nat Rev Dis Primers*.<br>440 2021:7:64. doi: 10.1038/s41572-021-00298-7 440 2021;7:64. doi: 10.1038/s41572-021-00298-7<br>441 7. Anderson L, Thompson DR, Oldridge N, Zw.
- 441 7. Anderson L, Thompson DR, Oldridge N, Zwisler AD, Rees K, Martin N, Taylor RS.<br>442 Exercise-based cardiac rehabilitation for coronary heart disease. *Cochrane Database* <sup>442</sup>Exercise-based cardiac rehabilitation for coronary heart disease. *Cochrane Database*
- <sup>443</sup>*Syst Rev*. 2016;2016:Cd001800. doi: 10.1002/14651858.CD001800.pub3 444 8. Pelliccia A, Sharma S, Gati S, Bäck M, Börjesson M, Caselli S, Collet J-P, Corrado D, <br>445 Drezner JA, Halle M, et al. 2020 ESC Guidelines on sports cardiology and exercise in 445 Drezner JA, Halle M, et al. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease: The Task Force on sports cardiology and
- patients with cardiovascular disease: The Task Force on sports cardiology and

exercise in patients with cardiovascular disease of the European Society of Cardiology<br>448 (ESC). *European Heart Journal*. 2021;42:17-96. doi: 10.1093/eurheartj/ehaa605 <sup>448</sup>(ESC). *European Heart Journal*. 2021;42:17-96. doi: 10.1093/eurheartj/ehaa605

- 449 9. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT,<br>450 Corrà U, Cosyns B, Deaton C, et al. 2016 European Guidelines on cardiovascular 450 Corrà U, Cosyns B, Deaton C, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European 451 disease prevention in clinical practice: The Sixth Joint Task Force of the European<br>452 Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in 452 Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in<br>453 Clinical Practice (constituted by representatives of 10 societies and by invited 453 Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for 454 experts)Developed with the special contribution of the European Association for<br>455 Cardiovascular Prevention & Rehabilitation (EACPR). *Eur Heart J*. 2016:37:2315-455 Cardiovascular Prevention & Rehabilitation (EACPR). *Eur Heart J.* 2016;37:2315-456 2381. doi: 10.1093/eurhearti/ehw106
- 456 2381. doi: 10.1093/eurheartj/ehw106<br>457 10. Judge DP, Dietz HC. Marfan's <sup>457</sup>10. Judge DP, Dietz HC. Marfan's syndrome. *Lancet*. 2005;366:1965-1976. doi:
- 458 10.1016/s0140-6736(05)67789-6<br>11. Mas-Stachurska A, Siegert AM 459 11. Mas-Stachurska A, Siegert AM, Batlle M, Gorbenko del Blanco D, Meirelles T,<br>460 Rubies C, Bonorino F, Serra Peinado C, Bijnens B, Baudin J, et al. Cardiovascular 460 Rubies C, Bonorino F, Serra Peinado C, Bijnens B, Baudin J, et al. Cardiovascular 461 Benefits of Moderate Exercise Training in Marfan Syndrome: Insights From an 461 Benefits of Moderate Exercise Training in Marfan Syndrome: Insights From an 462 Animal Model. Journal of the American Heart Association. 2017;6:e006438. doi: <sup>462</sup>Animal Model. *Journal of the American Heart Association*. 2017;6:e006438. doi:
- 463 10.1161/JAHA.117.006438<br>464 12. Gibson C, Nielsen C, Alex 464 12. Gibson C, Nielsen C, Alex R, Cooper K, Farney M, Gaufin D, Cui JZ, van Breemen<br>465 C, Broderick TL, Vallejo-Elias J, et al. Mild aerobic exercise blocks elastin fiber 465 C, Broderick TL, Vallejo-Elias J, et al. Mild aerobic exercise blocks elastin fiber<br>466 fragmentation and aortic dilatation in a mouse model of Marfan syndrome associated 466 **1.456** fragmentation and aortic dilatation in a mouse model of Marfan syndrome associated 467 contraction and apple  $I$  Apple Physiol (1985). 2017;123:147-160. doi: <sup>467</sup>aortic aneurysm. *J Appl Physiol (1985)*. 2017;123:147-160. doi: 468 10.1152/japplphysiol.00132.2017<br>169 13 Iouini S. Milleron O. Eliabou I
- 469 13. Jouini S, Milleron O, Eliahou L, Jondeau G, Vitiello D. Effects of a personalized<br>470 home-based training program among patients suffering from Marfan syndrome: a pilot 470 home-based training program among patients suffering from Marfan syndrome: a pilot randomized and controlled study. *Intractable Rare Dis Res.* 2021;10:263-268. doi: 471 randomized and controlled study. *Intractable Rare Dis Res.* 2021;10:263-268. doi:<br>472 10.5582/irdr.2021.01080
- 472 10.5582/irdr.2021.01080<br>473 14. Ware JE, Jr., Sherbourne 473 14. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I.<br>474 Conceptual framework and item selection. *Med Care*. 1992;30:473-483. 474 Conceptual framework and item selection. *Med Care*. 1992;30:473-483.<br>475 15. Benninghoven D. Hamann D. von Kodolitsch Y. Rybczynski M.
- 475 15. Benninghoven D, Hamann D, von Kodolitsch Y, Rybczynski M, Lechinger J, Schroeder F, Vogler M, Hoberg E. Inpatient rehabilitation for adult patients with 476 Schroeder F, Vogler M, Hoberg E. Inpatient rehabilitation for adult patients with<br>477 Marfan syndrome: an observational pilot study. Orphanet J Rare Dis. 2017;12:127. 477 Marfan syndrome: an observational pilot study. *Orphanet J Rare Dis.* 2017;12:127.<br>478 doi: 10.1186/s13023-017-0679-0
- 478 doi: 10.1186/s13023-017-0679-0<br>479 16. Cheng A, Owens D. Marfan synd 479 16. Cheng A, Owens D. Marfan syndrome, inherited aortopathies and exercise: what is the right answer? *Heart (British Cardiac Society)*. 2015;101:752-757. doi: 480 right answer? *Heart (British* 481 10.1136/heartinl-2014-306440 481 10.1136/heartjnl-2014-306440<br>482 17. Douard. Nouvelles recommand
- 482 17. Douard. Nouvelles recommandations pour la pratique du sport de compétition en cas<br>483 d'anomalie cardiovasculaire. Archives des Maladies du Coeur et des Vaisseaux -483 d'anomalie cardiovasculaire. *Archives des Maladies du Coeur et des Vaisseaux -* <br>484 *Pratique.* 2016;2016:27-30. doi: 10.1016/j.amcp.2016.01.010 <sup>484</sup>*Pratique*. 2016;2016:27-30. doi: 10.1016/j.amcp.2016.01.010
- 485 18. Vorp DA, Schiro BJ, Ehrlich MP, Juvonen TS, Ergin MA, Griffith BP. Effect of aneurysm on the tensile strength and biomechanical behavior of the ascending thoracic 486 aneurysm on the tensile strength and biomechanical behavior of the ascending thoracic<br>487 aorta. The Annals of Thoracic Surgery. 2003;75:1210-1214. doi: 10.1016/s0003-487 aorta. *The Annals of Thoracic Surgery*. 2003;75:1210-1214. doi: 10.1016/s0003-488 488 4975(02)04711-2<br>489 19. Haddad M. Stylia
- 489 19. Haddad M, Stylianides G, Djaoui L, Dellal A, Chamari K. Session-RPE Method for<br>490 Training Load Monitoring: Validity, Ecological Usefulness, and Influencing Factors. 490 Training Load Monitoring: Validity, Ecological Usefulness, and Influencing Factors.<br>491 *Frontiers in Neuroscience*. 2017;11. doi: 10.3389/fnins.2017.00612 <sup>491</sup>*Frontiers in Neuroscience*. 2017;11. doi: 10.3389/fnins.2017.00612
- 492 20. Foster C, Florhaug JA, Franklin J, Gottschall L, Hrovatin LA, Parker S, Doleshal P, 493 Dodge C. A new approach to monitoring exercise training. *J Strength Cond Res.* 493 Dodge C. A new approach to monitoring exercise training. *J Strength Cond Res*.<br>494 2001:15:109-115. 494 2001;15:109-115.<br>495 21. Rand-Hendriksen
- 495 21. Rand-Hendriksen S, Johansen H, Semb SO, Geiran O, Stanghelle JK, Finset A.<br>496 Health-related quality of life in Marfan syndrome: a cross-sectional study of Short <sup>496</sup>Health-related quality of life in Marfan syndrome: a cross-sectional study of Short

497 Form 36 in 84 adults with a verified diagnosis. *Genetics in Medicine: Official Journal* 498 *of the American College of Medical Genetics.* 2010;12:517-524. doi: 498 of the American College of Medical Genetics.<br>499 10.1097/GIM.0b013e3181ea4c1c 499 10.1097/GIM.0b013e3181ea4c1c<br>500 22. Vanem TT, Rand-Hendriksen S.

- 500 22. Vanem TT, Rand-Hendriksen S, Brunborg C, Geiran OR, Røe C. Health-related quality of life in Marfan syndrome: a 10-year follow-up. *Health Qual Life Outcomes*. 501 quality of life in Marfan syndrome: a 10-year follow-up. *Health Qual Life Outcomes*.<br>502 2020:18:376. doi: 10.1186/s12955-020-01633-4 502 2020;18:376. doi: 10.1186/s12955-020-01633-4<br>503 23. Hung C, Daub B, Black B, Welsh R, Quinney
- 503 23. Hung C, Daub B, Black B, Welsh R, Quinney A, Haykowsky M. Exercise training<br>504 improves overall physical fitness and quality of life in older women with coronary 504 improves overall physical fitness and quality of life in older women with coronary<br>505 artery disease. *Chest*. 2004;126:1026-1031. doi: 10.1378/chest.126.4.1026 505 artery disease. *Chest*. 2004;126:1026-1031. doi: 10.1378/chest.126.4.1026<br>506 24. Moholdt TT, Amundsen BH, Rustad LA, Wahba A, Løvø KT, Gullikstad
- 506 24. Moholdt TT, Amundsen BH, Rustad LA, Wahba A, Løvø KT, Gullikstad LR, Bye A, Skogvoll E, Wisløff U, Slørdahl SA. Aerobic interval training versus continuous 507 Skogvoll E, Wisløff U, Slørdahl SA. Aerobic interval training versus continuous<br>508 moderate exercise after coronary artery bypass surgery: a randomized study of 508 moderate exercise after coronary artery bypass surgery: a randomized study of cardiovascular effects and quality of life. American Heart Journal. 2009:158:1031-509 cardiovascular effects and quality of life. *American Heart Journal*. 2009;158:1031-<br>510 1037. doi: 10.1016/j.ahj.2009.10.003
- 510 1037. doi: 10.1016/j.ahj.2009.10.003<br>511 25. Giske L, Stanghelle JK, Rand-Heno 511 25. Giske L, Stanghelle JK, Rand-Hendrikssen S, Strøm V, Wilhelmsen J-E, Røe C.<br>512 Pulmonary function, working capacity and strength in young adults with Marfan 512 Pulmonary function, working capacity and strength in young adults with Marfan syndrome. Journal of Rehabilitation Medicine. 2003;35:221-228.
- 513 syndrome. *Journal of Rehabilitation Medicine*. 2003;35:221-228.<br>514 26. Percheron G, Fayet G, Ningler T, Le Parc J-M, Denot-Ledunois S 514 26. Percheron G, Fayet G, Ningler T, Le Parc J-M, Denot-Ledunois S, Leroy M, Raffestin<br>515 B, Jondeau G. Muscle strength and body composition in adult women with Marfan 515 B, Jondeau G. Muscle strength and body composition in adult women with Marfan<br>516 syndrome. *Rheumatology*. 2007;46:957-962. doi: 10.1093/rheumatology/kel450 516 syndrome. *Rheumatology.* 2007;46:957-962. doi: 10.1093/rheumatology/kel450<br>517 27. Tesch PA. Exercise performance and beta-blockade. *Sports Med.* 1985;2:389-41
- 517 27. Tesch PA. Exercise performance and beta-blockade. *Sports Med*. 1985;2:389-412. doi:<br>518 10.2165/00007256-198502060-00002 518 10.2165/00007256-198502060-00002<br>10.2165/00007256-198502060-00002
- 519 28. Davis EC. Smooth muscle cell to elastic lamina connections in developing mouse aorta. Role in aortic medial organization. *Lab Invest*. 1993;68:89-99. 520 aorta. Role in aortic medial organization. *Lab Invest*. 1993;68:89-99.<br>521 29. Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC, 31
- 521 29. Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC, 3rd. Angiotensin II<br>522 blockade and aortic-root dilation in Marfan's syndrome. *N Engl J Med*. 522 blockade and aortic-root dilation in Marfan's syndrome. *N Engl J Med*.<br>523 2008;358:2787-2795. doi: 10.1056/NEJMoa0706585 523 2008;358:2787-2795. doi: 10.1056/NEJMoa0706585<br>524
- 
- 525 525
- 527
- 528 528
- 529
- 531
- 531
- 532 533
- 535
- 535
- 537
- 538 538
- 540
- 540
- 542 542
- 543
- 545
- 545

555

557 558

558

559

561

562

562

563

<sup>564</sup>**Tables**  Table 1 : Characterisctics of MFS patients



<i><b>Other</b></i>	
Scoliosis $(n=)$	32
Sprained ankle $(n=)$	48
Pectus $(n=)$	27
Beighton score (mean)	

<sup>566&</sup>lt;br>567

567 MFS: Marfan Syndrome. H-S; Healthy Subjects. BMI: body mass index; E/A: left ventricle early to late filling ratio; FM: fat mass; MM: muscle mass; LVEF: left ventricular ejection 568 early to late filling ratio; FM: fat mass; MM: muscle mass; LVEF: left ventricular ejection<br>569 fraction; LV GLS: left ventricle global longitudinal strain; RV GLS: global longitudinal 569 fraction; LV GLS: left ventricle global longitudinal strain; RV GLS: global longitudinal strain. strain.



#### 571 **Table 2: The quality of life and its evolution with training in MFS patients**

572

573 H-S: healthy subjects. MFS-C: Marfan Controls. MFS-T : Marfan training. Δ pre post : difference between value at 3 months (post) and at 574 baseline (pre). At baseline MFS-C and MFS-T are significantly different from H-S for all parameters. After 3 months value changes were 575 significantly and different in the MFS-C an MFS and MFS

#### 576<br>577 <sup>577</sup>**Table 3 : Key parameters during training sessions for MFS patients**



578<br>579 579 Duration of training: total training time during protocol. HR peak: peak heart rate reached during training sessions. HR means Mean heart rate during the entire training sessions. RPE: 580 during training sessions. HR means Mean heart rate during the entire training sessions. RPE:<br>581 Rated Perceived Exertion Scale measured at the end of training session. BP1 Blood pressure 581 Rated Perceived Exertion Scale measured at the end of training session. BP1 Blood pressure<br>582 before starting the training session. BP2: blood pressure at mid-session, BP3: blood pressure 582 before starting the training session. BP2: blood pressure at mid-session, BP3: blood pressure at the end of training session. at the end of training session.

584



#### 585<br>586 <sup>586</sup>**Table 4: Cardiovascular and pulmonary effects of training in MFS patients**

587<br>588 588 Δ: pre to post variation. Alx: augmentation index. BP: blood pressure. EI: Elasticity Index. 589 LVEF: left ventricular ejection fraction. MFS-C: Marfan control. MFS-T: Marfan training. PEF: 590 Peak expiratory flow. PWV: pulse wave velocity. FEV1/FVC%: Tiffeneau index.

It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.05.16.23289922;](https://doi.org/10.1101/2023.05.16.23289922) this version posted May 18, 2023. The copyright holder for this preprint

- 591 **Figures legends : 592**
- 
- 592 <sup>593</sup>**Figure: 1 Flow chart.**

594<br>595

#### <sup>595</sup>**Figure 2a : Peak oxygen consumption**

596 Peak oxygen consumption ( $V\square$ O<sub>2</sub>peak) in H-S (healthy subjects), MFS-C (Marfan syndrome<br>597 control), and MFS-T (Marfan syndrome training), at baseline (base) and after 3 months (3M) 597 control), and MFS-T (Marfan syndrome training), at baseline (base) and after 3 months (3M).<br>598  $\Delta 3M$  is the difference after 3 months compared to baseline. †  $p<0.05$  when compared to 598  $\,\Delta$ 3M is the difference after 3 months compared to baseline. † p<0,05 when compared to 599 MFS-C Base and MFS-T Base.  $\,\sharp$  p<0,05 vs. MFS-T Base and MFS-C Base and post.  $\,\alpha$ : The <sup>599</sup>MFS-C Base and MFS-T Base. ‡ p<0,05 *vs.* MFS-T Base and MFS-C Base and post. ¤: The 600  $\,\Delta$ 3M is significantly greater in MFS-T than in MFS-C (p<0,05).<br>601

#### 602 <sup>602</sup>**Figure 2b Pulse wave velocity**

603 2b: Pulse wave velocity (PWV) after peak exercise. in H-S (healthy subjects), MFS-C (Marfan syndrome control), and MFS-T (Marfan syndrome training), at baseline (base) and 604 (Marfan syndrome control), and MFS-T (Marfan syndrome training), at baseline (base) and after 3 months (3M).  $\Delta 3M$  is the difference after 3 months compared to baseline. †  $p<0.05$ 605 after 3 months (3M).  $\Delta$ 3M is the difference after 3 months compared to baseline. † p<0,05 when compared to MFS-C Base and MFS-T Base.  $\pm$  p<0,05 vs. MFS-T Base and MFS-C 606 when compared to MFS-C Base and MFS-T Base.  $\ddagger$  p<0,05 *vs*. MFS-T Base and MFS-C 607 Base and post.  $\alpha$ : The  $\Delta 3M$  is significantly greater in MFS-T than in MFS-C (p<0,05). 607 Base and post. ¤: The  $\Delta 3M$  is significantly greater in MFS-T than in MFS-C (p<0,05).<br>608

#### 608 <sup>609</sup>*Figure 2c* **Blood pressure during an isometric squat exercise**

610 Blood pressure ( $BP = SBP$  and  $DBP$ ) is measured during an isometric squat exercise in H-S<br>611 (healthy subjects), MFS-C (Marfan syndrome control), and MFS-T (Marfan syndrome 611 (healthy subjects), MFS-C (Marfan syndrome control), and MFS-T (Marfan syndrome training), at baseline (base) and after 3 months  $(3M)$ .  $\Delta 3M$  is the difference after 3 months 612 training), at baseline (base) and after 3 months (3M).  $\Delta 3M$  is the difference after 3 months compared to baseline.  $\dagger$  p<0,05 when compared to MFS-C Base and MFS-T Base.  $\ddagger$  p<0,05 613 compared to baseline. † p<0,05 when compared to MFS-C Base and MFS-T Base. ‡ p<0,05 614 vs. MFS-T Base and MFS-C Base and post.  $\alpha$ : The  $\Delta 3M$  is significantly greater in MFS-T 614 *vs.* MFS-T Base and MFS-C Base and post.  $\alpha$ : The  $\Delta 3M$  is significantly greater in MFS-T than in MFS-C ( $p<0.05$ ). than in MFS-C ( $p<0.05$ ).

616

### <sup>617</sup>**Figure 2d Aortic root diameter**

618 Aortic root diameter is measured during an isometric squat exercise MFS-C (Marfan syndrome control), and MFS-T (Marfan syndrome training), at baseline (base) and after 3 619 syndrome control), and MFS-T (Marfan syndrome training), at baseline (base) and after 3 months  $(3M)$ .  $\Delta 3M$  is the difference after 3 months compared to baseline. No significant 620 months (3M). Δ3M is the difference after 3 months compared to baseline. No significant diffence were observed diffence were observed

622

#### <sup>623</sup>**Figure 3a: One repetition maximum (1RM) test for lower limbs**

624 time of the one repetition maximum (1RM). in H-S (healthy subjects), MFS-C (Marfan syndrome control), and MFS-T (Marfan syndrome training), at baseline (base) and after 3 625 syndrome control), and MFS-T (Marfan syndrome training), at baseline (base) and after 3 months (3M).  $\Delta$ 3M is the difference after 3 months compared to baseline. † p<0,05 when 626 months (3M).  $\Delta$ 3M is the difference after 3 months compared to baseline. † p<0,05 when compared to MFS-C Base and MFS-T Base.  $\pm$  p<0,05 *vs*. MFS-T Base and MFS-C Base and 627 compared to MFS-C Base and MFS-T Base.  $\ddagger$  p<0,05 *vs.* MFS-T Base and MFS-C Base and post.  $\alpha$ : The  $\Delta 3M$  is significantly greater in MFS-T than in MFS-C (p<0,05). post. ¤: The Δ3M is significantly greater in MFS-T than in MFS-C (p<0,05).

629

- 
- 030<br>634  $\frac{1}{2}$

#### <sup>632</sup>**Figure 3b: Elasticity Index (EI) assessed during vertical jump tests (CMJ-SJ)**

633 the elasticity index (EI) was assessed during vertical jump tests (CMJ-SJ) . in H-S (healthy subjects), MFS-C (Marfan syndrome control), and MFS-T (Marfan syndrome training), at

634 subjects), MFS-C (Marfan syndrome control), and MFS-T (Marfan syndrome training), at baseline (base) and after 3 months (3M).  $\Delta 3M$  is the difference after 3 months compared to

635 baseline (base) and after 3 months (3M).  $\Delta 3M$  is the difference after 3 months compared to 636 baseline. †  $p<0.05$  when compared to MFS-C Base and MFS-T Base.  $\ddagger$  p<0.05 vs. MFS-T

636 baseline. † p<0,05 when compared to MFS-C Base and MFS-T Base.  $\ddagger$  p<0,05 *vs.* MFS-T Base and MFS-C Base and post.  $\ddot{\text{z}}$ : The  $\Delta 3M$  is significantly greater in MFS-T than in MFS-C 637 Base and MFS-C Base and post. ¤: The  $\Delta 3M$  is significantly greater in MFS-T than in MFS-C ( $p < 0.05$ ).

 $(p<0.05)$ .





# **Figure 2**



Figure 2b: pulse wave velocity (PWV) after maximal exercise ok



Figure 2c: Blood pressure during an isometric squat exercise ok



Figure 2d: Aortic root diameter ok





## **FIGURE 3**

Figure 3a : First one-repetition maximum (1RM) test for lower limbs







### Figure 3b: Elasticity Index (EI) assessed during vertical jump tests (CMJ-SJ)